BioSpace News Archive

Business

BMS Invests in Protein Degradation, Cell Therapy Platforms

Bristol Myers Squibb entered two separate research collaboration and licensing deals, one with San Francisco-based SyntheX and the second with London’s Autolus Therapeutics.

October 4, 2022
·
3 min read
·
Mark Terry
Business

BlueSphere Bio’s Newly Minted CEO Calls for Urgency on Day One

With ambitions to enter the clinic in the first half of 2023, Keir Loiacono, esq., aims to double down on BlueSphere’s strengths rather than make any major course corrections.

October 4, 2022
·
4 min read
·
Gail Dutton
Drug Development

Araris Biotech AG Nabs $24M to Bring ADC, Linker Programs to Clinic

Araris Biotech AG secured $24 million in financing to advance the development of its proprietary antibody-drug conjugate (ADC)-linker technology and drive its own ADC candidates into the clinic.

October 4, 2022
·
3 min read
·
Alex Keown
Drug Development

Safety Concerns End KalVista Angioedema Trial

KalVista Pharmaceuticals announced Tuesday that life-threatening safety concerns prompted it to shut down a mid-stage clinical trial for hereditary angioedema.

October 4, 2022
·
2 min read
·
Paul Elias
Deals

Ginkgo Strengthens Cell and Gene Therapy Services with Circularis, Altar (Updated)

Ginkgo Bioworks opened its wallet Tuesday and snapped up Circularis and Altar to strengthen its cell and gene therapy programs and bolster its manufacturing capabilities.

October 4, 2022
·
3 min read
·
Alex Keown
Drug Development

Pfizer, Clovis Make Inroads Against Tough to Treat Prostate Cancer

Early data from the Phase III TALAPRO-2 study showed Talzenna, Pfizer’s oral PARP inhibitor, met its primary endpoint in metastatic castration-resistant prostate cancer patients.

October 4, 2022
·
2 min read
·
Tristan Manalac
Business

Sanofi, miRecule Ink Muscular Dystrophy Research Deal Worth up to $430M

miRecule inked Tuesday a research partnership and licensing deal with Sanofi worth $30 million that will advance a best-in-class antibody-RNA conjugate to treat FSHD.

October 4, 2022
·
3 min read
·
Mark Terry
Biotech Bay

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 04, 2022

Olema Pharmaceuticals, Inc. announced that the Company granted stock options to four new employees to purchase an aggregate of 58,300 shares of the Company’s common stock, effective as of October 3, 2022.

October 4, 2022
·
1 min read
BioCareSD Adds Six New Products to Existing Portfolio in Partnership with UCB

BioCareSD, a specialty distributor of life-saving therapies, today announced a contract with UCB to add six new product offerings to its already diverse portfolio

October 4, 2022
·
2 min read
Biotech Bay

Sense and Abacus dx Agree to Distribute Rapid, Instrument-Free Molecular COVID-19 Test in Australia and New Zealand

Global molecular diagnostics innovator Sense Biodetection announced it has entered into a strategic agreement with Abacus dx for the non-exclusive distribution in Australia and New Zealand of Sense’s Veros instrument-free, point-of-care molecular testing platform.

October 4, 2022
·
4 min read